4.4 Article

Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection

Journal

JOURNAL OF VIROLOGICAL METHODS
Volume 302, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.jviromet.2022.114469

Keywords

SARS-CoV-2; COVID-19; Antigenemia; Enzyme immunoassay; Nucleocapsid

Funding

  1. Helsinki University Hospital [TYH2019263, TYH2021110]

Ask authors/readers for more resources

This study aimed to characterize the specificity and sensitivity of an enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 nucleocapsid antigen in serum, and to describe the kinetics of antigenemia. The results showed high specificity and sensitivity of the test, providing accurate diagnosis of acute COVID-19.
SARS-CoV-2 RNA can be detected in respiratory samples for weeks after onset of COVID-19 disease. Therefore, one of the diagnostic challenges of PCR positive cases is differentiating between acute COVID-19 disease and convalescent phase. The presence of SARS-CoV-2 nucleocapsid antigen in serum and plasma samples of COVID-19 patients has been demonstrated previously. Our study aimed to characterize the analytical specificity and sensitivity of an enzyme-linked immunosorbent assay (Salocor SARS-CoV-2 Antigen Quantitative Assay Kit (c) (Salofa Ltd, Salo, Finland)) for the detection of SARS-CoV-2 nucleocapsid antigen in serum, and to characterize the kinetics of antigenemia. The evaluation material included a negative serum panel of 155 samples, and 126 serum samples from patients with PCR-confirmed COVID-19. The specificity of the Salocor SARS-CoV-2 serum nucleocapsid antigen test was 98.0 %. In comparison with simultaneous positive PCR from upper respiratory tract (URT) specimens, the test sensitivity was 91.7 %. In a serum panel in which the earliest serum sample was collected two days before the collection of positive URT specimen, and the latest 48 days after (median 1 day post URT sample collection), the serum N antigen test sensitivity was 95.6 % within 14 days post onset of symptoms. The antigenemia resolved approximately two weeks after the onset of disease and diagnostic PCR. The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to provide useful in-formation for timing of COVID-19. Our results suggest that SARS-CoV-2 N-antigenemia may be used as a diag-nostic marker in acute COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available